946126-97-2

Basic information

• Product Name: 2-oxo-2H-3-(2-fluoro-3-aminobenzyl)-4-methyl-7-hydroxy-1-benzopyran
• Synonyms: 2-oxo-2H-3-(2-fluoro-3-aminobenzyl)-4-methyl-7-hydroxy-1-benzopyran
• CAS NO: 946126-97-2
• Molecular Weight: 299.301
• Mol File: 946126-97-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-oxo-2H-3-(2-fluoro-3-aminobenzyl)-4-methyl-7-hydroxy-1-benzopyran(CAS DataBase Reference)
• NIST Chemistry Reference: 2-oxo-2H-3-(2-fluoro-3-aminobenzyl)-4-methyl-7-hydroxy-1-benzopyran(946126-97-2)
• EPA Substance Registry System: 2-oxo-2H-3-(2-fluoro-3-aminobenzyl)-4-methyl-7-hydroxy-1-benzopyran(946126-97-2)

Safety Data

• Hazardous Substances Data: 946126-97-2(Hazardous Substances Data)

Upstream product

• 3970-35-2 2-chloro-3-nitrobezoic acid 
• 946126-95-0 (2-fluoro-3-nitrophenyl)methanol 
• 946126-94-9 2-fluoro-3-nitrobenzoic acid methyl ester 
• 53553-14-3 2-chloro-3-nitrobenzoic acid methyl ester 
• 946130-07-0 2-(2-fluoro-3-nitrobenzyl)-3-oxo-butyric acid ethyl ester 
• 946125-65-1 1-(bromomethyl)-2-fluoro-3- nitrobenzene 
• 437-86-5 2-fluoro-3-nitrotoluene 
• 3970-40-9 2-chloro-3-nitrotoluene 
• 946130-13-8 3-(2-fluoro-3-nitrobenzyl)-7-hydroxy-4-methyl-2-oxo-2H-1-benzopyran 

Downstream Products

• 946126-61-0 4-methyl-3-(2-fluoro-3-aminobenzyl)-7-(thiazol-2-yloxy)-2-oxo-2H-1-benzopyran 
• 946126-42-7 4-methyl-3-(2-fluoro-3-aminobenzyl)-7-(pyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran 
• 946128-76-3 3-{2-fluoro-3-(methylaminosulfonyl)aminobenzyl}-4-methyl-7-(pyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran 
• 946129-85-7 2-{2-fluoro-3-[4-methyl-2-oxo-7-(pyrimidin-2-yloxy)-2H-1-benzopyran-3-ylmethyl]phenylsulfamoyl}-N-methylacetamide 
• 946127-42-0 4-fluoromethyl-3-(2-fluoro-3-aminobenzyl)-7-(thiazol-2-yloxy)-2-oxo-2H-1-benzopyran 
• 946126-93-8 C₂₃H₁₈FN₃O₇S 
• 946126-64-3 3-{2-fluoro-3-aminobenzyl}-4-methyl-7-(5-fluoropyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran 
• 946126-67-6 3-(2-fluoro-3-aminobenzyl)-4-methyl-7-(benzothiazol-2-yloxy)-2-oxo-2H-1-benzopyran 

Relevant articles and documents

p27 PROTEIN INDUCER

The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G 1 , G 2 , G 3 and G 8 are each independently selected from -N= etc., Ring G 6 is selected from divalent aryl etc., A is selected from amino etc., G 4 is selected from oxygen etc., G 5 is selected from oxygen etc., G 7 is selected from -CH 2 - etc., and R 2 is selected from C 1-6 alkyl etc.

Fluorine scanning by nonselective fluorination: Enhancing Raf/MEK inhibition while keeping physicochemical properties

A facile methodology effective in obtaining a set of compounds monofluorinated at various positions (fluorine scan) by chemical synthesis is reported. Direct and nonselective fluorination reactions of our lead compound 1a and key intermediate 2a worked efficiently to afford a total of six monofluorinated derivatives. All of the derivatives kept their physicochemical properties compared with the lead 1a and one of them had enhanced Raf/MEK inhibitory activity. Keeping physicochemical properties could be considered a benefit of monofluorinated derivatives compared with chlorinated derivatives, iodinated derivatives, methylated derivatives, etc. This key finding led to the identification of compound 14d, which had potent tumor growth inhibition in a xenograft model, excellent PK profiles in three animal species, and no critical toxicity.

NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY

The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y1 and Y2 are selected from -N= etc., Y3 and Y4 are selected from -CH= etc., A is selected from sulfamide etc., R1 is selected from hydrogen etc., and R2 is selected from C1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.